


RealRate

## PHARMACEUTICAL 2017

## VERTEX PHARMACEUTICALS INC MA Rank 53 of 313







## PHARMACEUTICAL 2017



## VERTEX PHARMACEUTICALS INC MA



Rate Rank 53 of 313

The relative strengths and weaknesses of VERTEX PHARMACEUTICALS INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERTEX PHARMACEUTICALS INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 336% points. The greatest weakness of VERTEX PHARMACEUTICALS INC MA is the variable Assets, Current, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 50%, being 467% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	1,831,540
Cost of Goods Sold	0
Intangible Assets	50,384
Liabilities, Current	792,537
Liabilities, Non-Current	102,122
Other Assets	316,501
Other Compr. Net Income	-8,672
Other Expenses	228,387
Other Liabilities	663,937
Other Net Income	-77,302
Property and Equipment	698,362
Research and Development	1,047,690
Revenues	1,702,177
Selling, General and Administrative Expense	432,829

Output Variable	Value in 1000 USD
Assets	2,896,787
Liabilities	1,558,596
Expenses	1,708,906
Stockholders Equity	1,338,191
Net Income	-84,031
Comprehensive Net Income	-88,367
Economic Capital Ratio	50%